TNBC is characterized by the absence of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER-2) expression (2) with a median overall survival (OS) rarely exceeding 12 to 18 months in advanced cancers (3). This evidence concerns the gene ESR1 and cancer.